Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
Bortezomib is a proteasome inhibitor, approved for treating newly diagnosed and relapsed multiple myeloma (MM). This realworld, multicenter, observational, non-interventional study of bortezomib was designed to collect and analyze prospective data in Taiwanese patients with relapsed or refractory MM...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-01-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | https://www.oncologyreviews.org/index.php/or/article/view/377 |